A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
雷莫芦单抗（一种针对 VEGF 受体 2 的人类单克隆抗体）作为晚期肝细胞癌患者的一线单药治疗的 II 期和生物标志物研究
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-13-1442
Andrew X Zhu, Richard S Finn, Mary Mulcahy, Jayne Gurtler, Weijing Sun, Jonathan D Schwartz, Rita P Dalal, Adarsh Joshi, Rebecca R Hozak, Yihuan Xu, Marek Ancukiewicz, Rakesh K Jain, Francis W Nugent, Dan G Duda, Keith Stuart
